{"record_key":"ecm-therapeutics-inc","identifier":"ecm-therapeutics-inc","external_key":"1CF044","title":"ECM Therapeutics, Inc.","summary":null,"url":"https://inventions.pitt.edu/startups/ecm-therapeutics-inc","json_url":"https://inventions.pitt.edu/startups/ecm-therapeutics-inc.json","object_key":"startups","description":"ECM Therapeutics develops regenerative materials designed to support tissue repair. Based in Warrendale, Pennsylvania, the company brings extracellular matrix hydrogel and matrix-bound nanovesicle technologies from Stephen Badylak’s University of Pittsburgh research into product development. Its cofounders include Badylak and Katie Collins. [1]: https://ecmtherapeutics.com/about/\nThe hydrogel platform can be formulated for injection, molding, coating or filling irregular spaces. Its pipeline includes an investigational fistula-repair treatment in Phase 1 and preclinical programs for gastrointestinal stricture and dermal filling. [2]: https://ecmtherapeutics.com/tissue-repair/\nThe company is evaluating ECMT-100 for anorectal fistulas in a first-in-human study. Separately, its ECMT-100 WMD wound-management product received FDA 510(k) clearance in June 2026. [3]: https://ecmtherapeutics.com/clinical/ [4]: https://ecmtherapeutics.com/news/","attributes":[{"key":"website","label":"Website","values":["https://ecmtherapeutics.com/"]},{"key":"sector","label":"Sector","values":["Medical Device"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Dermatology","Ophthalmology"]},{"key":"therapeutic_indications","label":"Therapeutic Indications","values":["Dry eye syndrome"]},{"key":"funding_stage","label":"Funding Stage","values":["Series A+"]},{"key":"founders","label":"Founders","values":["Stephen Badylak","Katie Collins"]}],"related":[]}